Antiamyloid Monoclonal Antibodies in Alzheimer's Disease, Part 1: Patient Selection

James R Bateman¹, Tara C Carlisle¹, Yanghong Yang¹+12

• ¹Department of Neurology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, N.C. (Bateman, Flashman); Department of Neurology, Behavioral Neurology Section, University of Colorado School of Medicine, Aurora (Carlisle, Pressman); Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, and Department of Neurology, SUNY Downstate Medical Center, New York City (Yang); Departments of Neurology and Psychiatry and Psychology, Mayo Clinic, Jacksonville, Fla. (Lachner); Department of Neurology, Cerebrovascular Division, Johns Hopkins University School of Medicine, Baltimore (Stockbridge); Department of Neurology, Harvard Medical School, Brigham and Women's Hospital, Boston (Chemali); Sakina Mental Health Services, SEHA, Abu Dhabi, United Arab Emirates (Alzbeidi); Department of Psychiatry, Atlantic Health System-Overlook Medical Center, Summit, N.J., and Department of Neurology, Icahn School of Medicine at Mount Sinai, New York City (Osibajo); Lower Merion Counseling Services, Lower Merion, Pa. (Bobrin); Department of Neurology, University of Texas Health Rio Grande Valley, Harlingen (Martinez-Menendez); Department of Neurology, Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio (Teixeira); Department of Neurology, Division of Cognitive and Behavioral Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston (Daffner).